Immuneering (IMRX) investor relations material

Strategic vision and innovation

• Focus on improving overall survival in First-Line pancreatic cancer through a new class of cancer medicines called Deep Cyclic Inhibitors, which employ three mechanisms: durable tumor shrinkage, preservation of body mass, and minimization of side effects.

• Atebimetinib, the lead Deep Cyclic Inhibitor, targets MEK in the MAP kinase pathway and is positioned as a triple threat to cancer, with broad applicability beyond pancreatic cancer, including ongoing studies in lung cancer.

• The approach departs from continuous pathway inhibition, instead using intermittent, high-intensity dosing to reduce resistance and improve tolerability by sparing healthy cells.

• MEK inhibitors, particularly atebimetinib, are shown to counteract cachexia, a major contributor to mortality in pancreatic cancer, by interfering with tumor-induced muscle breakdown.

• The company is actively expanding Deep Cyclic Inhibition to other targets in its preclinical pipeline, aiming to reduce side effects and resistance across multiple cancer types.

Clinical data and program updates

• Phase II data for atebimetinib in combination with chemotherapy showed 64% overall survival at 12 months in First-Line pancreatic cancer, nearly double the 35% benchmark from standard care.

• Median progression-free survival reached 8.5 months versus 5.5 months for chemotherapy alone; disease control and response rates were also higher than historical controls.

• 84% of patients were stable or gained weight at 3 months, and adverse events above grade 3 were limited to anemia and neutropenia, both attributed to chemotherapy, indicating excellent tolerability.

• About half of patients proceeded to subsequent therapies, mostly chemotherapy, consistent with literature for pancreatic cancer.

• Phase III MAPKeeper 301 trial is set to enroll 510 all-comer patients, with first patient dosing guided for mid-year; the primary endpoint is overall survival.

Competitive landscape and future directions

• Atebimetinib’s advantages over competitors include robust survival, weight preservation, and a favorable side effect profile compared to other MEK and RAS inhibitors.

• Calls for greater data transparency from competitors to allow patients and clinicians to make informed choices.

• Combination strategies include ongoing and planned studies with mutation-specific RAS inhibitors and Regeneron’s Libtayo in lung cancer, with first patient dosing in the lung study expected in the second half of the year.

• The MAP kinase pathway’s involvement in about half of all cancers suggests broad future applicability for Deep Cyclic Inhibitors.

• Updates on expanded pancreatic cancer cohorts and new indications are expected in the first half of the year.